Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.